Preliminary data from a Phase 1b dose escalation study of OP-1250, an oral CERAN, in combination with palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

被引：0
|
作者：
Chan, Arlene
Day, Daphne
Hui, Rina
McCarthy, Nicole
Wilson, Rosalind
Faltaos, Demiana
Shaw, Morena
Murphy, Caitlin
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P3-07-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-15
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer
    Neilan, Tomas G.
    Villanueva-Vazquez, Rafael
    Bellet, Meritxell
    Lopez-Miranda, Elena
    Garcia-Estevez, Laura
    Kabos, Peter
    Bond, John
    Gates, Mary R.
    Chang, Ching-Wei
    Boni, Valentina
    CANCER RESEARCH, 2022, 82 (04)
  • [42] Phase 1/2 dose-escalation and expansion study investigating SAR439859+/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2-metastatic breast cancer.
    Bardia, Aditya
    Linden, Hannah M.
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Celanovic, Marina
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: phase 1b cohort
    Hamilton, Erika
    Jeselsohn, Rinath
    Hurvitz, Sara
    Juric, Dejan
    Han, Hyo
    Telli, Melinda
    Zahrah, George
    Nanda, Rita
    Zhang, Yuanyuan
    Tan, Weiwei
    Duperret, Elizabeth
    Zhi, Eric
    Mather, Cecile
    Schott, Anne
    CANCER RESEARCH, 2024, 84 (09)
  • [44] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope S.
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara A.
    Loibl, Sibylle
    Kummel, Sherko
    Scartoni, Simona
    Matheny, Shannon
    Theall, Kathy Puyana
    O'shaughnessy, Joyce
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
  • [45] Real-world efficacy and safety of palbociclib combined with fulvestrant in japanese patients with ER-positive HER2-negative advanced or metastatic breast cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Shimizu, Ken
    Higeta, Kaori
    CANCER RESEARCH, 2020, 80 (04)
  • [46] A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
    Hamilton, Erika Paige
    Oliveira, Mafalda
    Banerji, Udai
    Hernando, Cristina
    Garcia-Corbacho, Javier
    Armstrong, Anne
    Ciruelos, Eva
    Patel, Manish R.
    Incorvati, Jason
    Twelves, Chris
    Brier, Tim
    Carroll, Danielle
    Fox, Steven
    Klinowska, Teresa
    Lindemann, Justin P. O.
    Mather, Richard
    Maudsley, Rhiannon
    McGuinness, Sam
    Sykes, Andy
    Baird, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer
    Darrigues, L.
    Pierga, J-Y
    Bernard, A.
    Bieche, I.
    Silveira, A.
    Michel, M.
    Sablin, M-P
    Cottu, P.
    Dubot, C.
    Geiss, R.
    Ricci, F.
    Proudhon, C.
    Bidard, F-C
    CANCER RESEARCH, 2019, 79 (04)
  • [48] A Phase.b Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage
    Wang, Jiayu
    Sun, Tao
    Zhang, Qingyuan
    Shi, Yanxia
    Wang, Xu
    Chen, Yiding
    Ouyang, Quchang
    Li, Kunyan
    Bupathi, Manojkumar
    Edenfield, W. Jeffery
    Silber, Andrea L. M.
    Zong, Hong
    Hamilton, Erika
    Juric, Dejan
    Lathrop, Kate
    Zhang, Yihong
    Stazzone, Kathryn
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Xu, Binghe
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study
    Li, Huiping
    Zhang, Qingyuan
    Li, Wei
    Wang, Shusen
    Liao, Ning
    Shen, Peng
    Shao, Bin
    Zhao, Wenhui
    Sun, Wan
    Yan, Ping
    Wang, Diane
    Li, Vince
    Linn, Carlos
    Shi, Haihong
    O'Gorman, Melissa
    Xu, Binghe
    LANCET ONCOLOGY, 2017, 18 : S7 - S7
  • [50] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Yoshimoto, Masataka
    Takao, Shintaro
    Hirata, Masaru
    Okamoto, Yasushi
    Yamashita, Sumio
    Kawaguchi, Yoshihiro
    Takami, Makoto
    Furusawa, Hidemi
    Morita, Satoshi
    Abe, Chigusa
    Sakamoto, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338
12345